Yakult Honsha licenses Japanese duvelisib rights from Verastem
Verastem Inc. granted Yakult Honsha Co. Ltd. exclusive rights to develop and sell duvelisib, a PI3K delta/PI3K gamma inhibitor, in Japan for all cancer indications.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com